NCT00932698 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- groups
- description
- Ixazomib 0.24 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
- id
- BG000
- title
- Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2
- description
- Ixazomib 0.48 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
- id
- BG001
- title
- Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2
- description
- Ixazomib 0.8 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
- id
- BG002
- title
- Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2
- description
- Ixazomib 1.2 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
- id
- BG003
- title
- Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2
- description
- Ixazomib 1.68 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
- id
- BG004
- title
- Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
- id
- BG005
- title
- Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2
- description
- Ixazomib 2.23 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
- id
- BG006
- title
- Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
- id
- BG007
- title
- Relapsed and Refractory Expansion Cohort: Ixazomib 2.0 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
- id
- BG008
- title
- Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
- id
- BG009
- title
- Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).
- id
- BG010
- title
- Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 7.02
- value
- 65.3
- group Id
- BG001
- spread
- 6.81
- value
- 61.3
- group Id
- BG002
- spread
- 12.10
- value
- 69.3
- group Id
- BG003
- spread
- 7.00
- value
- 66.0
- group Id
- BG004
- spread
- 9.85
- value
- 64.0
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 78
- group Id
- BG006
- spread
- 7.50
- value
- 64.3
- group Id
- BG007
- spread
- 9.58
- value
- 64.4
- group Id
- BG008
- spread
- 8.02
- value
- 65.4
- group Id
- BG009
- spread
- 6.84
- value
- 64.0
- group Id
- BG010
- spread
- 3.54
- value
- 71.5
- group Id
- BG011
- spread
- 8.25
- value
- 65.2
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 12
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 28
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 32
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 9
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 55
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Missing
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 18
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 54
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 5
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Other
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.63
- value
- 173.1
- group Id
- BG001
- spread
- 7.60
- value
- 167.5
- group Id
- BG002
- spread
- 4.54
- value
- 167.4
- group Id
- BG003
- spread
- 14.25
- value
- 180.1
- group Id
- BG004
- spread
- 7.90
- value
- 165.4
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 178
- group Id
- BG006
- spread
- 12.18
- value
- 169.7
- group Id
- BG007
- spread
- 11.28
- value
- 165.8
- group Id
- BG008
- spread
- 13.26
- value
- 165.7
- group Id
- BG009
- spread
- 9.16
- value
- 169.3
- group Id
- BG010
- spread
- 6.08
- value
- 156.7
- group Id
- BG011
- spread
- 11.07
- value
- 167.5
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 59
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- Here, number analyzed are the participants who were evaluated for this baseline measure.
- title
- Height
- unit Of Measure
- centimeter (cm)
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.560
- value
- 87.50
- group Id
- BG001
- spread
- 5.937
- value
- 71.03
- group Id
- BG002
- spread
- 5.036
- value
- 74.87
- group Id
- BG003
- spread
- 12.760
- value
- 109.90
- group Id
- BG004
- spread
- 2.542
- value
- 80.77
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 82.3
- group Id
- BG006
- spread
- 21.532
- value
- 82.98
- group Id
- BG007
- spread
- 23.760
- value
- 77.81
- group Id
- BG008
- spread
- 15.579
- value
- 72.60
- group Id
- BG009
- spread
- 16.811
- value
- 93.20
- group Id
- BG010
- spread
- 36.770
- value
- 71.70
- group Id
- BG011
- spread
- 19.946
- value
- 80.27
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Weight
- unit Of Measure
- kilogram (kg)
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.192
- value
- 2.05
- group Id
- BG001
- spread
- 0.100
- value
- 1.82
- group Id
- BG002
- spread
- 0.062
- value
- 1.86
- group Id
- BG003
- spread
- 0.229
- value
- 2.34
- group Id
- BG004
- spread
- 0.071
- value
- 1.93
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 2.02
- group Id
- BG006
- spread
- 0.335
- value
- 1.97
- group Id
- BG007
- spread
- 0.342
- value
- 1.88
- group Id
- BG008
- spread
- 0.237
- value
- 1.82
- group Id
- BG009
- spread
- 0.265
- value
- 2.09
- group Id
- BG010
- spread
- 0.495
- value
- 1.74
- group Id
- BG011
- spread
- 0.291
- value
- 1.92
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 59
- units
- Participants
- description
- Body Surface Area (m\^2)=\[Height(cm) \* Weight (kg)\]/3600)\^1/2.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- Here, number analyzed are the participants who were evaluated for this baseline measure.
- title
- Body Surface Area
- unit Of Measure
- meter square
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 55
- upper Limit
- 291
- value
- 59.1
- group Id
- BG001
- lower Limit
- 57
- upper Limit
- 94
- value
- 61.8
- group Id
- BG002
- lower Limit
- 34
- upper Limit
- 152
- value
- 45.8
- group Id
- BG003
- lower Limit
- 46
- upper Limit
- 88
- value
- 80.4
- group Id
- BG004
- lower Limit
- 13
- upper Limit
- 58
- value
- 38.4
- group Id
- BG005
- lower Limit
- 44.62
- upper Limit
- 44.62
- value
- 44.62
- group Id
- BG006
- lower Limit
- 21
- upper Limit
- 85
- value
- 35.2
- group Id
- BG007
- lower Limit
- 19
- upper Limit
- 124
- value
- 56.9
- group Id
- BG008
- lower Limit
- 12
- upper Limit
- 151
- value
- 42.7
- group Id
- BG009
- lower Limit
- 61
- upper Limit
- 97
- value
- 71.9
- group Id
- BG010
- lower Limit
- 46
- upper Limit
- 106
- value
- 76.1
- group Id
- BG011
- lower Limit
- 12
- upper Limit
- 291
- value
- 57.4
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Time Since Primary Diagnosis to First Dose
- unit Of Measure
- months
- population Description
- Safety population included all participants who received at least 1 dose of ixazomib. A total of 60 participants participated in the study. There were 7 participants in Dose Escalation Cohort 6: Ixazomib 2.0 mg/m\^2 arm group, 6 out of 7 participated in both phases of the study and were counted once in the expansion cohort.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- groups
- description
- Ixazomib 0.24 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
- id
- BG000
- title
- Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2
- description
- Ixazomib 0.48 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
- id
- BG001
- title
- Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2
- description
- Ixazomib 0.8 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
- id
- BG002
- title
- Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2
- description
- Ixazomib 1.2 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
- id
- BG003
- title
- Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2
- description
- Ixazomib 1.68 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
- id
- BG004
- title
- Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
- id
- BG005
- title
- Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2
- description
- Ixazomib 2.23 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
- id
- BG006
- title
- Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
- id
- BG007
- title
- Relapsed and Refractory Expansion Cohort: Ixazomib 2.0 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
- id
- BG008
- title
- Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \>=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
- id
- BG009
- title
- Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2
- description
- Ixazomib 2.0 mg/m\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).
- id
- BG010
- title
- Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 7.02
- value
- 65.3
- group Id
- BG001
- spread
- 6.81
- value
- 61.3
- group Id
- BG002
- spread
- 12.10
- value
- 69.3
- group Id
- BG003
- spread
- 7.00
- value
- 66.0
- group Id
- BG004
- spread
- 9.85
- value
- 64.0
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 78
- group Id
- BG006
- spread
- 7.50
- value
- 64.3
- group Id
- BG007
- spread
- 9.58
- value
- 64.4
- group Id
- BG008
- spread
- 8.02
- value
- 65.4
- group Id
- BG009
- spread
- 6.84
- value
- 64.0
- group Id
- BG010
- spread
- 3.54
- value
- 71.5
- group Id
- BG011
- spread
- 8.25
- value
- 65.2
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 12
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 28
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 32
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 9
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 55
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Missing
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 18
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 54
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 5
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Other
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.63
- value
- 173.1
- group Id
- BG001
- spread
- 7.60
- value
- 167.5
- group Id
- BG002
- spread
- 4.54
- value
- 167.4
- group Id
- BG003
- spread
- 14.25
- value
- 180.1
- group Id
- BG004
- spread
- 7.90
- value
- 165.4
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 178
- group Id
- BG006
- spread
- 12.18
- value
- 169.7
- group Id
- BG007
- spread
- 11.28
- value
- 165.8
- group Id
- BG008
- spread
- 13.26
- value
- 165.7
- group Id
- BG009
- spread
- 9.16
- value
- 169.3
- group Id
- BG010
- spread
- 6.08
- value
- 156.7
- group Id
- BG011
- spread
- 11.07
- value
- 167.5
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 59
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- Here, number analyzed are the participants who were evaluated for this baseline measure.
- title
- Height
- unit Of Measure
- centimeter (cm)
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.560
- value
- 87.50
- group Id
- BG001
- spread
- 5.937
- value
- 71.03
- group Id
- BG002
- spread
- 5.036
- value
- 74.87
- group Id
- BG003
- spread
- 12.760
- value
- 109.90
- group Id
- BG004
- spread
- 2.542
- value
- 80.77
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 82.3
- group Id
- BG006
- spread
- 21.532
- value
- 82.98
- group Id
- BG007
- spread
- 23.760
- value
- 77.81
- group Id
- BG008
- spread
- 15.579
- value
- 72.60
- group Id
- BG009
- spread
- 16.811
- value
- 93.20
- group Id
- BG010
- spread
- 36.770
- value
- 71.70
- group Id
- BG011
- spread
- 19.946
- value
- 80.27
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Weight
- unit Of Measure
- kilogram (kg)
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.192
- value
- 2.05
- group Id
- BG001
- spread
- 0.100
- value
- 1.82
- group Id
- BG002
- spread
- 0.062
- value
- 1.86
- group Id
- BG003
- spread
- 0.229
- value
- 2.34
- group Id
- BG004
- spread
- 0.071
- value
- 1.93
- comment
- Standard deviation is not estimable for 1 participant.
- group Id
- BG005
- spread
- NA
- value
- 2.02
- group Id
- BG006
- spread
- 0.335
- value
- 1.97
- group Id
- BG007
- spread
- 0.342
- value
- 1.88
- group Id
- BG008
- spread
- 0.237
- value
- 1.82
- group Id
- BG009
- spread
- 0.265
- value
- 2.09
- group Id
- BG010
- spread
- 0.495
- value
- 1.74
- group Id
- BG011
- spread
- 0.291
- value
- 1.92
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 59
- units
- Participants
- description
- Body Surface Area (m\^2)=\[Height(cm) \* Weight (kg)\]/3600)\^1/2.
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- Here, number analyzed are the participants who were evaluated for this baseline measure.
- title
- Body Surface Area
- unit Of Measure
- meter square
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 55
- upper Limit
- 291
- value
- 59.1
- group Id
- BG001
- lower Limit
- 57
- upper Limit
- 94
- value
- 61.8
- group Id
- BG002
- lower Limit
- 34
- upper Limit
- 152
- value
- 45.8
- group Id
- BG003
- lower Limit
- 46
- upper Limit
- 88
- value
- 80.4
- group Id
- BG004
- lower Limit
- 13
- upper Limit
- 58
- value
- 38.4
- group Id
- BG005
- lower Limit
- 44.62
- upper Limit
- 44.62
- value
- 44.62
- group Id
- BG006
- lower Limit
- 21
- upper Limit
- 85
- value
- 35.2
- group Id
- BG007
- lower Limit
- 19
- upper Limit
- 124
- value
- 56.9
- group Id
- BG008
- lower Limit
- 12
- upper Limit
- 151
- value
- 42.7
- group Id
- BG009
- lower Limit
- 61
- upper Limit
- 97
- value
- 71.9
- group Id
- BG010
- lower Limit
- 46
- upper Limit
- 106
- value
- 76.1
- group Id
- BG011
- lower Limit
- 12
- upper Limit
- 291
- value
- 57.4
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 20
- group Id
- BG008
- value
- 12
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 60
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Time Since Primary Diagnosis to First Dose
- unit Of Measure
- months
- population Description
- Safety population included all participants who received at least 1 dose of ixazomib. A total of 60 participants participated in the study. There were 7 participants in Dose Escalation Cohort 6: Ixazomib 2.0 mg/m\^2 arm group, 6 out of 7 participated in both phases of the study and were counted once in the expansion cohort.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle